J&J Innovation Centers report 12 new partners, investments
This article was originally published in Scrip
Johnson & Johnson's Innovation Centers are living up to their promise of supporting early-stage drug, device and consumer product development with 60 investments or partnerships under their collective belt to date, including 12 recently announced transactions.
You may also be interested in...
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.